SCHEMBL5134301

SCHEMBL5134301

CS(=O)(=O)C1(N)N=CN=C(N2CCC(c3nc(-c4cccc(C(F)(F)F)c4)no3)CC2)C1(c1ccccc1)[N+](=O)[O-]

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 2/20 0.52
HTT P42858 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
LMNA P02545 2/20 0.41
GAA P10253 2/20 0.41
GRM5 P41594 2/20 0.40
MEN1 O00255 1/20 0.39
MAPT P10636 1/20 0.39
RECQL P46063 1/20 0.39
KMT2A Q03164 1/20 0.39
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
S1PR1 P21453 1/20 0.36
DPP4 P27487 2/20 0.35
DPP7 Q9UHL4 2/20 0.35
KIT P10721 1/20 0.35
DPP8 Q6V1X1 1/20 0.35
TP53 P04637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3683246 0.69 GPR119 (0.70) GPR119HTTSMN1; SMN2LMNAGAA
SCHEMBL390342 0.68 GPR119 (1.00) GPR119HTTSMN1; SMN2LMNAMEN1
SCHEMBL3120943 0.67 GRM5 (0.55) GPR119HTTSMN1; SMN2LMNAGAA
SCHEMBL29871272 0.64 NR1H4 (0.62) HTTSMN1; SMN2LMNAGAAGRM5
SCHEMBL24844566 0.63 NPSR1 (0.48) GPR119HTTSMN1; SMN2LMNAGAA
SCHEMBL31741445 0.63 NPSR1 (0.48) GPR119HTTSMN1; SMN2LMNAGAA
SCHEMBL3723661 0.63 GRM5 (0.63) HTTSMN1; SMN2LMNAGAAGRM5
SCHEMBL3975387 0.62 GPR119 (0.52) GPR119HTTSMN1; SMN2LMNAGAA
SCHEMBL8244892 0.61 GRM5 (0.51) HTTSMN1; SMN2LMNAGAAGRM5
SCHEMBL29876315 0.60 GPR119 (0.43) GPR119HTTSMN1; SMN2LMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2004157-A2 USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AS WELL AS COMBINATION THERAPY RELATING THERETO Arena Pharmaceuticals, Inc. (US) 2008-12-24 EP disclosed
WO-2007120702-A2 USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AND COMBINATION THERAPY RELATING THERETO ARENA PHARMACEUTICALS, INC. (US) 2007-10-25 WO disclosed